ALK and non-small cell lung carcinoma: In contrast with chemotherapy alone, sintilimab, an anti-PD-1 antibody, combined with chemotherapy contributed to better clinical benefit, with PFS of 8.9 versus 5.0 months and ORR of 51.9% versus 29.8% in the first-line setting for the treatment of metastatic in NSCLC patients without EGFR or ALK mutations [184, 185].